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Abstract 
Background: Pulmonary hypertension (PH) is among the complications of HIV infection. 
Combination antiretroviral therapy may influence the progression of HIV-related PH. 
Because Akt signaling is a potential molecular target of HIV protease inhibitors (HPIs), we 
hypothesized that these drugs altered monocrotaline- and hypoxia-induced PH in rats by 
downregulating the Akt pathway, thereby inhibiting pulmonary-artery smooth-muscle-cell 
(PA-SMC) proliferation. 
Methods and Results: Daily treatment with each of three first-generation HPIs (ritonavir, 
30 mg/kg; amprenavir, 100 mg/kg; and nelfinavir, 500 mg/kg) started 3 weeks after a 
subcutaneous monocrotaline injection (60 mg/kg) substantially diminished pulmonary artery 
pressure, right ventricular hypertrophy, number of muscularized pulmonary vessels, 
pulmonary arterial wall thickness, and proliferating pulmonary vascular Ki67-labeled cells, 
without affecting vessel caspase 3 staining. HPI treatment partially prevented the 
development of hypoxia and monocrotaline-induced PH. Monocrotaline-induced PH was 
associated with marked activation of Akt signaling in the lungs and proximal pulmonary 
arteries, with increases in p-Akt, p-glycogen-synthase-kinase-3β (p-GSK3), and p-
endothelial NO-synthase (eNOS), all of which decreased markedly after treatment with each 
HPI. In contrast, PH-associated increases in phosphorylated extracellular signal-related 
kinase 1/2 (Erk1/2) and myosin light-chain phosphatase (MYPT) were unaltered by the 
HPIs. The three HPIs and the phosphatidylinositol 3-kinase inhibitor LY294002 inhibited 
PDGF-induced phosphorylation of Akt and GSK3 in cultured PA-SMCs and blocked cell 
proliferation; this last effect was abolished by the GSK3 inhibitor SB216763.  
Conclusions: These results support an effect of HPIs on pulmonary vascular remodeling 
mediated by inhibition of Akt phosphorylation and, consequently, of PA-SMC proliferation.  
Key words: AIDS; pulmonary heart disease; remodeling; muscle, smooth  
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INTRODUCTION 
Pulmonary hypertension (PH) can occur as a life-threatening vascular complication 
of HIV infection 
1
. Survival gains in HIV-infected patients have translated into an increase in 
the prevalence of PH, which has been estimated at 0.5% in this population, that is, about 
1000-fold higher than the prevalence of idiopathic PH in the general population.
2,3
 HIV 
infection may account for about 7% of all PH cases and 10% of cases accompanied with 
portal hypertension.
2,3
. The clinical presentation and underlying pathology of HIV-related 
PH are similar to those of idiopathic or associated PH, with marked structural remodeling of 
the pulmonary vessels leading to an increase in pulmonary vascular resistance.
4
  
The prevalence of HIV-related PH seems unchanged compared to the 1990s, before 
the introduction of highly active antiretroviral therapy (HAART).
2,3
 However, the potential 
impact of combination antiretroviral therapy on the progression of HIV-related PH is still 
under investigation, and the effects of antiretroviral drugs on pulmonary function and 
hemodynamics remain controversial. HAART was associated with improved hemodynamics 
and survival in some studies
5,6
 and with improved exercise tolerance but unchanged 
pulmonary hemodynamics in others.
7,8
 The effect of HAART in these studies showed 
considerable interindividual variability, with some patients achieving near-normal 
pulmonary artery pressures and others experiencing either no change or a further pressure 
increase.
7-9
 Thus, an important and still unresolved question is whether antiretroviral 
therapy, and more specifically HIV protease inhibitors (HPIs), interfere with 
pathophysiological processes underlying the pulmonary vascular remodeling that occurs 
during PH progression.  
HPIs are peptidomimetics that inhibit the HIV enzyme aspartyl protease required to 
produce infectious viral particles.
10
 Interference of HPIs with host-cell functions leads to a 
number of side effects such as insulin resistance, diabetes, and dyslipidemia
11
. HPIs have 
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been shown to inhibit cancer cell growth in vitro and cancer growth in vivo in experimental 
animals.
12-14
 One possible mechanism of this growth-inhibiting effect, and perhaps also of 
the insulin resistance-inducing effect, is inhibition of the Akt signaling pathway.
12-14
 In 
pulmonary artery smooth muscle cells (PA-SMCs), Akt signaling is a downstream target of 
several factors such as PDGF
15, 16
and serotonin,
17
 which are important mediators of the 
pulmonary vascular remodeling process.
18,19
 Because PH is primarily a proliferative disease, 
and because the Akt pathway has been shown in vitro to mediate smooth muscle cell 
proliferation via phosphorylation and inactivation of its downstream effector glycogen-
synthase-kinase-3 (GSK-3),20 we hypothesized that HPIs slowed PH progression by 
interfering with the Akt signaling pathway.  
We therefore designed the present study to investigate whether three first-generation 
HPIs (ritonavir, amprenavir, and nelfinavir) altered monocrotaline- and hypoxia-induced PH 
in rats; whether alterations in the Akt signaling pathway occurred during PH progression; 
and whether effects of HPIs on the Akt signaling pathway decreased PA-SMC growth, 
thereby diminishing pulmonary vascular remodeling. In parallel, we investigated the 
potential effects of HPIs on the MAP kinase and RhoA signaling pathways by measuring the 
phosphorylation of extracellular signal-related kinase 1/2 (ERK1/2) and myosin light-chain 
phosphatase (MYPT). 
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METHODS  
Animal model and experimental design  
All experiments were performed in adult male Wistar rats (200-250 g) according to 
institutional guidelines complying with national and international regulations. PH was 
induced by administering 60 mg/kg of monocrotaline (Sigma-Aldrich, Lyon, France) 
subcutaneously or by exposing rats to 10% O2 in a ventilated chamber (Biospherix, New-
york, USA) for 21 days.  To assess the potential curative effects of HPIs, rats given 
monocrotaline were left untreated for 21 days then randomly assigned to treatment with 
ritonavir (30 mg/kg), amprenavir (100 mg/kg), nelfinavir (500 mg/kg), or vehicle from day 
21 to day 42 (10 animals in each group). All treatments were given by gavage, once a day 
except for nelfinavir, which was given twice daily. The ritonavir dose was close to that used 
in humans; the amprenavir dose was selected based on information from the manufacturer, 
to obtain in rats the plasma levels achieved in humans; and the nelfinavir dose was selected 
based on preliminary studies showing decreased effectiveness with lower doses. Rats in each 
group were sacrificed on days 28 and 42 for assessments of treatment effects after 1 and 3 
weeks. In another series of experiments, rats were treated with HPIs for 3 weeks either after 
monocrotaline injection or during hypoxia exposure then sacrificed for assessment of PH. 
Additional studies were also performed at various times after monocrotaline injection for 
assessments of Akt signaling during PH development.  
 
Assessment of pulmonary hypertension  
Rats were anesthetized with ketamine (60 mg/kg i.m.) and xylazine (3 mg/kg i.m.). A 
polyvinyl catheter was introduced into the right jugular vein and pushed through the right 
ventricle into the pulmonary artery.
21
 After measurement of pulmonary (Pap) and systemic 
(Sap) arterial pressures, the thorax was opened and the left lung and proximal pulmonary 
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arteries were immediately removed and frozen in liquid nitrogen for protein immunoblotting. 
The heart was dissected and weighed for calculation of the right ventricular hypertrophy 
index (ratio of right ventricular free wall weight over sum of septum plus left ventricular free 
wall weight: RV/LV+S). The right lung was fixed in the distended state with formalin 
buffer. After paraffin embedding, 5-m thick lung sections were stained with hematoxylin-
phloxin-saffron. In each rat, the distribution and degree of artery muscularization were 
assessed by categorizing 40-60 intraacinar arteries as muscular, partially muscular, or 
nonmuscular. Normalized arterial wall thickness was calculated as the ratio of the difference 
between external and internal diameter over external diameter of the pulmonary artery.  
 
Evaluation of in situ PA-SMC death and proliferation 
Proliferation and apoptosis of PA-SMCs were assessed using Ki67 and caspase 3 
immunostaining. Tissue sections were deparaffinized in xylene, treated with a graded series 
of alcohol washes, rehydrated, and incubated in citrate buffer (0.01 M, pH 6) at 90°C for 20 
minutes. Endogenous peroxidase activity was blocked with 3% H2O2 and 10% methanol in 
PBS for 10 minutes. Slides were first incubated for 60 minutes in 1% bovine serum albumin 
and 5% goat serum in PBS then incubated overnight with anti-Ki67 rabbit antibody (1:500, 
Abcam, Cambridge, MA, USA) and anti-caspase 3 active rabbit antibody (1:200, R&D 
Systems, Minneapolis, MN, USA). The slides were incubated with biotinylated goat anti-
rabbit antibody (1:200, Vector Labs, Burlingame, CA, USA) and the signal was then 
developed using an immunoperoxidase reagent (ABC-HRP, Vector Labs) and DAB (Sigma-
Aldrich) as the substrate.  
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Effects of HPIs on isolated PA-SMC proliferation and apoptosis 
PA-SMCs from rat pulmonary arteries were cultured and characterized as previously 
described 
21
. Before treatment, PA-SMCs were placed for 24 hours in DMEM with 0.1% 
serum. The cells were exposed to ritonavir, amprenavir, nelfinavir, the selective 
phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002, or vehicle in serum-free medium 
for 24 hours then treated with PDGF-BB (10 ng/ml). After 48 hours, tetrazolium salt (MTT), 
(Sigma, Lyon, France) was added to each well (0.2 mg/ml). After 4 hours’ incubation at 
37°C, the culture medium was removed and formazan crystals were solubilized by adding 
100 L of DMSO. Tetrazolium salt reduction to formazan within the cells was quantified by 
spectrophotometry at 520 nm and taken as an indicator of the number of cells.  
Annexin V flow cytometry was performed
 
using a commercially available annexin V 
fluorescein isothiocyanate
 
(FITC) assay (Sigma-Aldrich). Cells were trypsinized and 
resuspended in media at 1x10
6
cells/mL then incubated with annexin V-FITC–conjugated 
antibody and stained with propidium iodide according to the manufacturer’s instructions. 
Annexin V staining and propidium iodide staining were detected by FACS (Becton 
Dickinson, Franklin Lakes, NJ, USA). Apoptotic cells were propidium iodide-positive cells 
and annexin V/ propidium iodide-positive cells. 
 
Western Blot analysis 
Akt, GSK3, ERK 1/2, MYPT, and endothelial nitric oxide synthase (eNOS) proteins 
were detected and measured in lung tissues and/or cells using Western blotting. Total protein 
from lung tissue (60 g) or cell sample (30 g) was subjected to 10% SDS-PAGE, and the 
separated proteins were transferred onto PVDF membranes (Millipore, Molsheim, France). 
After incubation in blocking solution (TBS/5% milk), the membranes were incubated 
sequentially with the following antibodies: anti-p-Akt, anti-Akt, anti-p-GSK3, anti-GSK3, 
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anti-ERK 1/2, and anti-p-ERK 1/2 (Cell Signaling Technology, Boston, USA); anti eNOS, 
and anti p-eNOS
S1177
 (BD Transduction Laboratories, Franklin Lakes, USA); anti MYPT1 
and anti p-MYPT1
Thr696
 (Upstate, Euromedex, Munolsheim, France); and anti–β-actin 
(Sigma, Saint-Quentin-Fallavier, France). Densitometric quantification was normalized for 
the beta-actin level in each sample (Gene Tools, Ozyme, Montigny le Bretonneux, France).  
 
Drugs 
Amprenavir was a gift from GlaxoSmithKline (Les Ulis, France) and was supplied as a 
powder to be dissolved in DMSO. Ritonavir and nelfinavir were obtained from the pharmacy 
of the Henri Mondor Teaching Hospital, Créteil, France. Ritonavir came as gelatin capsules, 
which were punctured to enable recovery of the content, a viscous liquid that was dissolved 
in 100% ethanol to produce a concentrated stock solution for use in the experiments. 
Nelfinavir was available as solid caplets that were ground into a fine powder then dissolved 
in water or PBS. The phosphatidylinositol 3-kinase (PI3K) inhibitor LY924002 was obtained 
from Calbiochem (San Diego, USA) and the glycogen-synthase-kinase-3 (GSK3) inhibitor 
SB216763 from Sigma (Lyon, France).  
 
Statistical analyses  
The data are described as mean±SEM. Parametric tests were used after verification 
that the variables in each group were normally distributed. Two-way analysis of variance 
(ANOVA) was performed to compare HPI treatment effects at various times after 
monocrotaline administration. Comparisons of treatments (three HPIs and vehicle) at a given 
time point were performed using one-way ANOVA. One-way ANOVA was also used to 
evaluate the time-dependent effects of monocrotaline administration on Akt signaling and to 
compare data from isolated PA-SMCs treated with various HPI doses. When a significant 
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difference was found, group means were compared using the modified t test. P values lower 
than 0.05 were considered significant. 
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RESULTS  
 
Effects of HIV protease inhibitors on progression of monocrotaline-induced pulmonary 
hypertension 
Rats examined 21 days after monocrotaline administration had severe PH with marked 
increases in Pap, RV/LV+S, and pulmonary-artery muscularization compared to control rats 
injected with saline instead of monocrotaline (Fig 1-2). Pulmonary artery pressure (Pap), 
right ventricular hypertrophy, and pulmonary vessel wall thickness increased further 
between day 21 and day 42 in the monocrotaline-treated rats given the vehicle instead of HPI 
(Fig 1-2). Daily administration of ritonavir (30 mg/kg), amprenavir (100 mg/kg), or 
nelfinavir (500 mg/kg) from day 21 to day 42 after monocrotaline injection led to marked 
decreases in Pap, right ventricular hypertrophy, number of muscularized pulmonary vessels, 
and pulmonary arterial wall thickness, compared to vehicle-treated rats (Fig 1-2). Treatment 
with any of the three HPIs also markedly reduced the number of Ki67-stained cells in the 
media of remodeled pulmonary vessels, without affecting caspase 3 staining (Fig 3). The 
decrease in Ki67-stained cells was already apparent on day 28, after only 1 week of HPI 
treatment, compared to the vehicle-treated animals. Rats treated with the three HPIs did not 
differ from vehicle-treated rats with respect to systemic arterial pressure and heart rate (data 
not shown). Studies were also performed to assess the preventive effects of HPIs on PH 
development. Treatment of rats with HPIs during exposure to chronic hypoxia or after 
monocrotaline injection attenuated the development of PH as judged on Pap, right 
ventricular hypertrophy, and pulmonary-artery muscularization (Fig. 4).  
 
Inhibition of Akt signaling by HIV protease inhibitors in lungs and proximal 
pulmonary arteries from monocrotaline-treated rats  
CIRCULATIONAHA/2010/973750 
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Although large amounts of Akt and GSK3 protein were found in the lungs and 
proximal pulmonary arteries of the control animals, only traces of p-Akt and p-GSK3 were 
detected. Monocrotaline administration was followed by a gradual p-Akt increase in the 
lungs and proximal pulmonary arteries, with no change in total Akt (Fig 5A). Similarly, p-
GSK3 levels increased gradually in the proximal pulmonary arteries, reaching a peak on day 
42 (Fig 5A). Lung p-Akt levels were also increased in chronically hypoxic rats compared to 
normoxic rats (data not shown). Treatment with ritonavir, amprenavir, or nelfinavir from day 
21 to day 42 after monocrotaline injection was associated with a large decrease in lung p-Akt 
and with considerably lower p-Akt and p-GSK3 levels in the proximal pulmonary arteries 
compared to the monocrotaline-injected vehicle-treated controls (Fig 5B). Compared to the 
monocrotaline-injected rats treated with vehicle instead of an HPI, the rats given 1 week of 
HPI treatment (day 28 after the monocrotaline injection) had lower p-Akt levels in the lungs 
and proximal pulmonary arteries, despite only small changes in pulmonary vessel 
muscularization. Similarly, lung p-eNOS levels, which increased in monocrotaline-treated 
rats compared to control rats, were markedly reduced by treatment with the three HPIs (Fig. 
6A). In contrast, p-ERK 1/2 and p-MYPT levels, which increased in the pulmonary arteries 
and lungs, respectively, from monocrotaline-treated rats, showed no significant changes in 
response to HPI treatment (Fig 6B, 6C). 
 
Inhibition of Akt signaling by HIV protease inhibitors in cultured pulmonary artery 
smooth muscle cells (PA-SMC) 
Pretreatment of PA-SMCs with ritonavir, amprenavir, or nelfinavir for 24 h led to 
dose-dependent inhibition of PDGF-induced cell proliferation. Inhibition was complete with 
20 M of ritonavir, 10 M of amprenavir, 50 M of nelfinavir, or 30 M of LY924002 (Fig. 
7A). Increasing the ritonavir concentration resulted in cell toxicity, as shown by the decrease 
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in MTT-labeled cells below the pre-PDGF count with a simultaneous increase in the 
apoptotic cell count. At doses below the toxic level, ritonavir, amprenavir, and LY924002 
inhibited growth without increasing apoptosis; whereas nelfinavir at the highest 
concentration of 50 M increased the apoptotic cell count (Fig 7A). Cell pretreatment with 
amprenavir, nelfinavir, ritonavir, or LY924002 dose-dependently inhibited PDGF-induced 
phosphorylation of Akt and GSK3 (Fig 7B). Phosphorylation of Akt or GSK3 was 
completely inhibited by ritonavir, nelfinavir, or LY924002; in contrast, even the highest 
amprenavir dose only partially inhibited the phosphorylation of Akt (by 20%) and GSK3 (by 
50%). These HPI-induced changes in p-Akt and p-GSK3 were not accompanied with 
changes in nonphosphorylated Akt or GSK3 (Fig 7B). Because p-GSK3 is inactive, we 
investigated whether inhibition of the active (nonphosphorylated) form of GSK3 abolished 
the growth-inhibiting effects of HPIs or LY924002 on PA-SMCs stimulated with PDGF. 
Treatment of the cells with the GSK3 inhibitor SB216763 completely abolished the 
inhibitory effect of amprenavir, nelfinavir, and LY924002 and almost completely abolished 
the inhibitory effect of ritonavir (Fig. 8). 
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DISCUSSION  
Our main finding is that the HIV protease inhibitors ritonavir, amprenavir, and 
nelfinavir reversed or attenuated the progression of PH induced in rats by monocrotaline 
injection or hypoxia exposure. In both models, PH development was associated with marked 
activation of the Akt signaling pathway in the lungs and proximal pulmonary arteries. 
Ritonavir, amprenavir, or nelfinavir given to monocrotaline-injected rats inhibited Akt 
phosphorylation in the lungs and pulmonary arteries and decreased the number of 
muscularized pulmonary vessels without altering p-ERK or p-MYPT levels. In addition, the 
three HPIs inhibited PDGF-induced phosphorylation of Akt and GSK3 in cultured PA-
SMCs and blocked PA-SMC proliferation. Taken together, these results support the ability 
of HPIs to interfere with pulmonary vascular remodeling by inhibiting Akt phosphorylation 
and, consequently, PA-SMC proliferation.  
That HPIs may interfere with the PI3K-Akt axis was suggested by several previous 
studies of tumor cells
12,13,14
. The PI3K-Akt axis is a major pathway for cell proliferation and 
cancer. This pathway is often activated in tumor cells but not in normal host cells and may 
therefore hold considerable promise as a target for future treatments against cancer
22
. PH is 
primarily a proliferative disorder that shares several features with cancer
23
. We reasoned that 
the Akt pathway may be activated in PH and that HPIs may interact with the pulmonary 
vascular cell proliferation that underlies PH progression. We found that the development of 
monocrotaline- and hypoxia-induced PH in rats was associated with marked activation of the 
Akt-GSK3 axis, as shown by increased phosphorylation of Akt and GSK3 in the lungs and 
proximal pulmonary arteries. Akt activation occurred early during PH development, within 
the first week after the monocrotaline injection, concomitantly with induction of the PA-
SMC proliferation that underlies the structural remodeling of pulmonary vessels. Cultured 
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rat PA-SMCs in the quiescent state showed no Akt pathway activation but exhibited marked 
PDGF-induced phosphorylation of Akt and GSK3. Among the various intracellular 
downstream effectors of Akt, GSK3 phosphorylation and inactivation of is considered the 
main mechanism controlling cell proliferation
20
. Our data are consistent with this concept, 
since PA-SMC treatment with LY294002, a specific PI3K inhibitor that blocked PDGF-
induced phosphorylation of Akt and GSK3, completely abolished the growth-promoting 
effect of PDGF. Furthermore, studies of human PA-SMCs showed that PI3K activity was 
both necessary and sufficient to mediate mitogen-induced cell proliferation and migration 
17
. 
Interestingly, the LY294002 doses used in our study to block Akt and to inhibit PA-SMC 
growth did not induce apoptosis. Taken together, these findings indicate clearly that 
activation of the Akt/GSK3 signaling pathway is a major contributor to PA-SMC growth and 
that rats given monocrotaline or exposed to hypoxia exhibit marked activation of this 
pathway.  
The main goal of this study was to investigate the ability of three HPIs to affect 
pulmonary vascular remodeling in vivo. In rats with established monocrotaline-induced PH, 
daily HPI treatment started 3 weeks after the monocrotaline injection produced large 
decreases in Pap, right ventricular hypertrophy, number of muscularized pulmonary vessels, 
and pulmonary arterial wall thickness compared to monocrotaline-injected vehicle-treated 
rats. Similar reductions in these parameters were obtained when the drugs were given 
preventively, before the onset of PH, to rats exposed to monocrotaline or hypoxia. In 
monocrotaline-treated rats with established PH, ritonavir, amprenavir, or nelfinavir given for 
only 1 week significantly decreased pulmonary arterial wall thickness and the number of 
Ki67-labeled cells in the pulmonary vascular wall without inducing major changes in 
caspase 3 staining. These in vivo results are consistent with a main effect of HPIs mediated 
by cell proliferation inhibition rather than by apoptosis induction. The absence of a pro-
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apoptotic effect probably explains why none of the HPIs tested induced complete PH 
reversal. Although the partial nature of the reversal seen with HPI treatment might be 
ascribable to the use of insufficient dosages, increasing the dosage was limited by poor 
tolerance, especially with ritonavir. Moreover, the dosages used in our study replicate those 
given to human patients and may therefore reflect the effects of the serum concentrations 
achieved clinically.
12,14
 The effect on PH progression was not markedly different across the 
three HPIs used in our study, and inhibition of pulmonary vascular remodeling by HPIs may 
therefore constitute a class effect. Moreover, our results suggest that the three drugs may act 
on pulmonary vascular remodeling via a common mechanism.  
Because regulation of cell proliferation and motility is a critical step in pulmonary 
vascular remodeling, researchers are focusing on the development of treatments that 
specifically target PA-SMC proliferation. Drugs targeting the PIK3-Akt pathway have not 
been evaluated as possible treatments for PH. All three HPIs evaluated in our study inhibited 
the phosphorylation of Akt and of its downstream effector GSK3. The effects of the HPIs 
were observed both in vitro and in vivo. The in vitro effects of the three HPIs were very 
similar to those of the selective PI3K inhibitor LY294002, with a marked decrease in cell 
proliferation contrasting with a small effect on cell apoptosis. The HPI doses required in 
vitro to block PDGF-induced Akt phosphorylation and PA-SMC proliferation were also 
similar to those of the specific PI3K inhibitor LY294002 and to those of the HPIs shown in 
previous studies to inhibit tumor cell growth and to block Akt signaling
12-14
. Thus, our 
finding that the HPIs inhibited Akt suggests mediation of HPI effects by inhibition of GSK3 
phosphorylation, i.e., GSK3 activation. Accordingly, cell treatment with a GSK3 inhibitor 
completely abolished the growth-inhibiting effects of amprenavir, nelfinavir, and LY294002 
and markedly decreased the inhibitory effect of ritonavir. We also found that each of the 
three HPIs decreased p-Akt in the lungs and pulmonary vessels. To determine whether this 
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effect preceded or was secondary to the changes in pulmonary vascular remodeling, we 
studied rats after only 1 week of HPI treatment, when only minor changes in pulmonary 
artery muscularization had occurred. The decreases in p-Akt and p-GSK3 in the pulmonary 
arteries at this time point, together with the decrease in Ki67-labeled cells in the vascular 
walls, are consistent with a primary effect of HPI treatment on the Akt signaling pathway, 
with secondary inhibition of PA-SMC proliferation. At this time point, HPI treatment did not 
affect the phosphorylation of Erk or MYPT, indicating that HPIs did not interfere with these 
signaling pathways.  
Our results in an experimental model of monocrotaline-induced PH support a 
protective role of HPIs against HIV-related PH. However, several HPIs including ritonavir, 
have been reported to induce endothelial dysfunction in systemic arteries of HIV-infected 
patients and to diminish endothelium-dependent relaxation and endothelial nitric oxide 
expression in porcine pulmonary arteries and human pulmonary endothelial cells
24
. Because 
the expression and activity of endothelial nitric oxide synthase (eNOS) are dependent on Akt 
signaling, the same pharmacological effects of HPIs may lead to two apparently opposite 
vascular effects, one exerted on endothelial cells and responsible for a decrease in eNOS 
activation with subsequent endothelial dysfunction, and the other exerted on PA-SMCs and 
responsible for inhibition of cell proliferation. Our results are consistent with this possibility. 
We found that eNOS protein levels remained unchanged in lungs from monocrotaline-
treated rats, in keeping with previous studies showing either unchanged or decreased lung 
eNOS protein levels in this model 
25
 
26
. However, lung p-eNOS, which increased markedly 
in monocrotaline-treated rats, decreased to basal levels after HPI treatment. Because PA-
SMC proliferation is the most prominent abnormality in monocrotaline-induced PH in rats, 
the antiproliferative effect of HPIs probably played a major role in slowing PH progression 
in our HPI-treated monocrotaline-injected rats.  
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The relevance of our findings to patients with HIV-related PH must be considered 
with circumspection. Although the HPI doses used in our study animals were chosen based 
on the plasma levels achieved in humans, the nelfinavir dosage needed to obtain an effect 
was higher than the dosage used clinically. Thus, our results are consistent with a 
pharmacological action of HPIs in humans, but other parameters may interfere with HPI 
effects on the Akt pathway in vivo, including drug pharmacokinetics, concomitant drugs, 
and side effects, as well as patient characteristics. Prominent side effects of HPI treatment 
include insulin resistance; diabetes; and dyslipidemia with increases in low-density 
lipoprotein (LDL)-cholesterol and triglycerides, body fat accumulation, and lipodystrophy.
11
 
Previous studies also suggest that diminished Akt activity in response to insulin may lead to 
insulin resistance.
27
 Thus, insulin resistance, a cause of glucose intolerance and 
dyslipidemia, may be one of the consequences of Akt inhibition by HPIs in HIV-infected 
patients.
28
 Whether the ability of HPIs to inhibit Akt in vivo is useful for treating patients 
with PH deserves to be investigated.  
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Figure legends 
Figure 1. Pulmonary artery pressure (Pap), right ventricular hypertrophy index 
[(RV/(LV+S) weight ratio], and muscularization of pulmonary vessels in rats studied at 
various times after administration of monocrotaline (MCT) or saline (controls). 
Muscularization of pulmonary vessels is reported as the percentages of nonmuscularized, 
partially muscularized, and fully muscularized distal vessels. Treatment with amprenavir 
(A), ritonavir (B), nelfinavir (C), or vehicle was given from day 21 to day 42 (n=10 in each 
group), in separate experiments for each drug including different controls. *P<0.05, 
**P<0.01, and ***P<0.001 compared with corresponding values recorded on day 28 or 42 
in the monocrotaline-injected vehicle-treated rats. 
 
Figure 2.  Pulmonary vascular remodeling. Representative photomicrographs of pulmonary 
vessels (A) and pulmonary artery wall thickness (B) from rats on day 21, 28, and 42 after 
saline (controls) or monocrotaline (MCT) administration. Each value is mean±SEM of 10 
independent determinations. * P<0.05 and ** P<0.01 compared with corresponding values 
recorded on day 28 or 42 in monocrotaline-injected vehicle-treated rats.  
 
Figure 3. A. Rat pulmonary-artery smooth-muscle-cell (PA-SMC) proliferation (Ki67 
staining, upper sections) on days 28 and 42 after monocrotaline (MCT) injection. Brown 
staining indicates Ki-67-positive cells. The number of proliferating vascular cells expressed 
as the percentage of Ki-67 labeled cells over the total number of cells counted in the media 
of at least 20 muscularized vessels per rat was markedly reduced by treatment with each of 
the HPIs, *P<0.05 and **P<0.01 compared with corresponding values recorded on day 28 or 
42 in the monocrotaline-injected vehicle-treated rats (n=10 in each group). B. Rat PA-SMC 
apoptosis (Caspase 3 staining, lower sections) on days 28 and 42 after monocrotaline 
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injection. The number of apoptotic cells (caspase 3-positive cells) was not affected by HPI 
treatment (n=10 in each group). Bar=50 µm.  
 
Figure 4. Pulmonary artery pressure, right ventricular hypertrophy index [(RV/(LV+S) 
weight ratio], muscularization of pulmonary vessels (percentage of partially and fully 
muscularized pulmonary vessels), and pulmonary artery wall thickness in rats studied on day 
21 after administration of monocrotaline or exposure to hypoxia. Control rats were studied 
after saline administration and kept in normoxic conditions. Treatment with amprenavir, 
ritonavir, nelfinavir, or vehicle was given from day 0 to day 21 (n=10 in each group). * 
P<0.05 and ** P<0.01 compared with values in vehicle-treated rats after monocrotaline 
administration or exposure to hypoxia.   
 
Figure 5. A. Time-course of Akt expression and Akt phosphorylation in lung tissue and 
proximal pulmonary arteries after monocrotaline (MCT) injection. Protein expression and 
phosphorylation were evaluated by western blot in rat lung and pulmonary artery extracts 7, 
21, 28, and 42 days after MCT administration. The column graph shows the mean±SEM 
values obtained in pulmonary arteries (n=10 in each group) * P<0.05; ** P<0.01; and 
***P<0.001 compared with values obtained before MCT administration. B. Changes in pAkt 
levels in lungs and changes in p-Akt and p-GSK3 levels in proximal pulmonary arteries 
measured 28 and 42 days after monocrotaline injection. Treatment with ritonavir, 
amprenavir, nelfinavir, or vehicle was given from day 21 to day 42 (n=10 in each group). 
*P<0.05; **P<0.01; and ***P<0.001 compared with values obtained in monocrotaline-
injected vehicle-treated rats. 
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Figure 6. Changes in p-eNOS and eNOS levels in lung (A), changes in p-Erk and Erk levels 
in proximal pulmonary arteries (B) and changes in p-MYPT and MYPT levels in lung (C) in 
rats injected with saline (controls) or monocrotaline, measured 28 days after monocrotaline 
injection. Treatment with ritonavir, amprenavir, nelfinavir, or vehicle was started at day 21 
(n=10 in each group). * P<0.05; ** P<0.01; and ***P<0.001 compared with values obtained 
in monocrotaline-injected vehicle-treated rats. 
 
Figure 7. A. Effects of ritonavir, amprenavir, nelfinavir, and LY924002 on pulmonary-
artery smooth-muscle-cell (PA-SMC) proliferation (column graph) and apoptosis (diamond 
graph). The cells were starved of fetal calf serum for 48 h and exposed to the HPIs or 
LY924002 at increasing concentrations during 24 hours. Cellular proliferation was measured 
using the tetrazolium assay 48 h after stimulation by 10 ng/ml of PDGF-BB. Apoptotic cells 
were determined at the same time. Values are mean±SEM of 12 values obtained from four 
independent experiments. * P<0.05; ** P<0.01; and ***P<0.001 compared with values 
obtained with PDGF alone. The apoptotic cell number increased in response to the 50µM 
concentration of ritonavir and nelfinavir (* P<0.05); B. Effects of treatment with 
amprenavir, ritonavir, nelfinavir, or LY924002 on p-Akt and p-GSK3 protein levels in 
cultured PA-SMC stimulated with 10 ng/ml of PDGF for 48 hours. Values are mean±SEM 
of 12 values obtained from four independent experiments. *P<0.05; **P<0.01; ***P<0.001 
compared to values obtained with PDGF alone. 
 
Figure 8. The GSK3 inhibitor SB216763 (10 µM) abolished the inhibitory effect of ritonavir 
(20 µM), amprenavir (30 µM), nelfinavir (50 µM), and LY924002 (30 µM) on PA-SMC 
proliferation. Values represent the percentage of cell numbers measured after stimulation 
with PDGF and are the mean±SEM of 12 values obtained from four independent 
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experiments. *P<0.05; **P<0.01; ***P<0.001 compared to values obtained with PDGF 
alone; †P<0.05 compared to values obtained with PDGF plus SB216763 (10 µM). 
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Figure 1 
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Figure 2 
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 Figure 3 
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Figure 4 
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Figure 5 A 
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Figure 5 B 
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Figure 6 A 
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Figure 6 B, C 
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Figure 7 A  
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Figure 7 B 
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Figure 8 
 
 
 
 
 
 
 
 
 
 
 
